CHARACTERISTICS OF INOSITOL 1,4,5-TRISPHOSPHATE BINDING TO RAT CEREBELLAR AND BOVINE ADRENAL-CORTICAL MEMBRANES - EVIDENCE FOR THE HETEROGENEITY OF BINDING-SITES

被引:0
|
作者
WILLCOCKS, AL [1 ]
CHALLISS, RAJ [1 ]
NAHORSKI, SR [1 ]
机构
[1] UNIV LEICESTER,DEPT PHARMACOL & THERAPEUT,LEICESTER LE1 9HN,ENGLAND
基金
英国惠康基金;
关键词
INOSITOL 1,4,5-TRISPHOSPHATE; RECEPTOR HETEROGENEITY; CEREBELLUM; ADRENAL CORTEX; HEPARIN;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The equilibrium and kinetic binding characteristics of D-inositol 1,4,5-trisphosphate (Ins(1,4,5)P3) have been studied in membrane preparations of rat cerebellum and bovine adrenal cortex. Saturation analysis of isotopic dilution binding data demonstrated apparent K(D) values for Ins(1,4,5)P3 binding of 23 +/- 5 nM and 3.0 +/- 1.3 nM for cerebellar and adrenal cortical preparations, respectively, with approximately 20-fold greater receptor density present in the cerebellar preparation (B(max): 10.2 +/- 2.5 pmol/mg protein). Kinetic analysis confirmed the equilibrium binding-derived K(D) value for cerebellum (K(D): 39.9 nM), but revealed a second, very high affinity site (K(D): 0.06 nM) to be present in adrenal cortex. The affinity differences between the investigated preparations was also observed with respect to the IC50 values obtained for inhibition of specific [H-3]Ins(1,4,5)P3 binding by a number of inositol polyphosphate analogues including D-inositol 2,4,5-trisphosphate, DL-inositol 1,4,5-trisphosphorothioate and L-Ins(1,4,5)P3. In contrast, the Ins(1,4,5)P3-receptor antagonist heparin displayed greater potency for the cerebellar (IC50: 16.5 +/- 6.2 mu-g. ml-1) compared to the adrenal cortical preparation (IC50: 51.0 +/- 6.1-mu-g. ml-1). The apparent differences between the Ins(1,4,5)P3 receptors characterized in the two tissue preparations are discussed.
引用
收藏
页码:185 / 193
页数:9
相关论文
共 50 条
  • [1] HETEROGENEITY OF [H-3] INOSITOL 1,4,5-TRISPHOSPHATE BINDING-SITES IN ADRENAL-CORTICAL MEMBRANES - CHARACTERIZATION AND VALIDATION OF A RADIORECEPTOR ASSAY
    CHALLISS, RAJ
    CHILVERS, ER
    WILLCOCKS, AL
    NAHORSKI, SR
    BIOCHEMICAL JOURNAL, 1990, 265 (02) : 421 - 427
  • [2] CHARACTERIZATION OF [H-3] INOSITOL 1,4,5-TRISPHOSPHATE BINDING-SITES IN HUMAN TEMPORAL CORTICAL AND CEREBELLAR MEMBRANES
    GARLIND, A
    COWBURN, RF
    FOWLER, CJ
    NEUROCHEMISTRY INTERNATIONAL, 1994, 24 (01) : 73 - 80
  • [3] POSSIBLE BINDING-SITES FOR INOSITOL 1,4,5-TRISPHOSPHATE IN MACROPHAGES
    ISHIMATSU, T
    KIMURA, Y
    IKEBE, T
    YAMAGUCHI, K
    KOGA, T
    HIRATA, M
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1988, 155 (03) : 1173 - 1180
  • [4] DIFFERENT LOCALIZATION OF INOSITOL 1,4,5-TRISPHOSPHATE AND RYANODINE BINDING-SITES IN RAT-LIVER
    FENG, L
    PEREIRA, B
    KRAUSFRIEDMANN, N
    FASEB JOURNAL, 1992, 6 (01): : A247 - A247
  • [5] DIFFERENT LOCALIZATION OF INOSITOL 1,4,5-TRISPHOSPHATE AND RYANODINE BINDING-SITES IN RAT-LIVER
    FENG, L
    PEREIRA, B
    KRAUSFRIEDMANN, N
    CELL CALCIUM, 1992, 13 (02) : 79 - 87
  • [6] INOSITOL 1,4,5-TRISPHOSPHATE BINDING-SITES ARE THE CALCIUM MOBILIZING RECEPTORS IN LIVER
    NUNN, DL
    TAYLOR, CW
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1990, 183 (06) : 2179 - 2179
  • [7] Ethanol and phosphatidylethanol reduce the binding of [H-3]inositol 1,4,5-trisphosphate to rat cerebellar membranes
    Rodriguez, FD
    Lundqvist, C
    Alling, C
    Gustavsson, L
    ALCOHOL AND ALCOHOLISM, 1996, 31 (05): : 453 - 461
  • [8] COMPARISON OF INOSITOL 1,4,5-TRISPHOSPHATE AND INOSITOL 1,3,4,5-TETRAKISPHOSPHATE BINDING-SITES IN CEREBELLUM
    CHALLISS, RAJ
    WILLCOCKS, AL
    POTTER, BVL
    NAHORSKI, SR
    BIOCHEMICAL SOCIETY TRANSACTIONS, 1991, 19 (02) : S151 - S151
  • [9] BINDING-SITES FOR INOSITOL TRISPHOSPHATE IN THE BOVINE ADRENAL-CORTEX
    BAUKAL, AJ
    GUILLEMETTE, G
    RUBIN, R
    SPAT, A
    CATT, KJ
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1985, 133 (02) : 532 - 538
  • [10] HIGH AND LOW AFFINITY INOSITOL TETRAKISPHOSPHATE BINDING-SITES IN BOVINE ADRENAL-CORTICAL MICROSOMES
    ENYEDI, P
    WILLIAMS, GH
    CLINICAL RESEARCH, 1988, 36 (03): : A552 - A552